New hope for kids with tough cancers: experimental combo shows promise

NCT ID NCT02512926

Completed Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a three-drug combination (carfilzomib, cyclophosphamide, and etoposide) in 4 children whose solid tumors or leukemias had come back or didn't respond to standard treatment. The main goal was to find the safest dose and identify side effects. The study is complete, but results are not yet widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leukemia Recurrence refractory hematologic cancer refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY LEUKEMIA REFRACTORY SOLID TUMORS RELAPSED LEUKEMIA RELAPSED SOLID TUMORS

Contacts and locations

Show contact details

Locations

Alberta Children's Hospital

Calgary, Alberta, T3B 6A8, Canada
Arkansas Children's Hospital

Little Rock, Arkansas, 72202, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
Penn State Hershey Children's Hospital

Hershey, Pennsylvania, 17033-0850, United States
Phoenix Children's Hospital

Phoenix, Arizona, 85016, United States
Stanford University School of Medicine and Stanford Cancer Institute

Palo Alto, California, 94304, United States
University of Texas Health Science Center at San Antonio

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.